TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 19)

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.4 CURRENCY

1.5 LIMITATIONS

1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 22)

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

2.2 MARKET SIZE ESTIMATION

2.2.1 BOTTOM-UP APPROACH

2.2.2 GROWTH FORECAST

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 28)

4 PREMIUM INSIGHTS (Page No. - 32)

4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE TISSUE DIAGNOSTIC MARKET

4.2 ASIA PACIFIC MARKET: BY DISEASE

4.3 TISSUE DIAGNOSTIC MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW (Page No. - 35)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing incidence of cancer

5.2.1.2 Growing healthcare expenditure

5.2.1.3 Developing infrastructure for cancer diagnosis

5.2.1.4 Recommendations for cancer screening

5.2.1.5 Availability of reimbursements

5.2.2 RESTRAINTS

5.2.2.1 High degree of consolidation

5.2.3 OPPORTUNITIES

5.2.3.1 Significant opportunities in BRICS countries

5.2.3.2 Growing demand for personalized medicines

5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs

5.2.4 CHALLENGES

5.2.4.1 Stringent regulatory requirements

5.2.4.2 Lack of infrastructure and low awareness in middle- and low- income countries

5.2.4.3 Availability of refurbished products

5.2.4.4 Lack of skilled professionals

5.2.4.5 Product failures and recalls

5.2.5 TRENDS

5.2.5.1 Increasing number of reagent rental agreements

6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 45)

6.1 INTRODUCTION

6.2 CONSUMABLES

6.2.1 ANTIBODIES

6.2.2 KITS

6.2.3 REAGENTS

6.2.4 PROBES

6.3 INSTRUMENTS

6.3.1 SLIDE-STAINING SYSTEMS

6.3.2 SCANNERS

6.3.3 TISSUE-PROCESSING SYSTEMS

6.3.4 OTHER INSTRUMENTS

7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 55)

7.1 INTRODUCTION

7.2 IMMUNOHISTOCHEMISTRY (IHC)

7.3 IN SITU HYBRIDIZATION (ISH)

7.4 DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT

7.5 SPECIAL STAINING

8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. - 61)

8.1 INTRODUCTION

8.2 BREAST CANCER

8.3 GASTRIC CANCER

8.4 LYMPHOMA

8.5 PROSTATE CANCER

8.6 NON-SMALL CELL LUNG CANCER (NSCLC)

8.7 OTHER DISEASES

9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. - 73)

9.1 INTRODUCTION

9.2 HOSPITALS

9.3 RESEARCH LABORATORIES

9.4 PHARMACEUTICAL COMPANIES

9.5 CONTRACT RESEARCH ORGANIZATIONS

9.6 OTHER END USERS

10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. - 78)

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 US

10.2.1.1 US is expected to be dominant country-level market for tissue diagnostics

10.2.2 CANADA

10.2.2.1 High prevalence of cancer in Canada is expected to support market growth

10.3 EUROPE

10.3.1 GERMANY

10.3.1.1 Availability of reimbursements for colorectal cancer screening

10.3.2 UK

10.3.2.1 Government initiatives to drive the growth in the UK

10.3.3 FRANCE

10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support the market growth

10.3.4 ITALY

10.3.4.1 High incidence of cancer to support the market growth in Italy

10.3.5 SPAIN

10.3.5.1 High incidence of chronic diseases to drive the Spanish market

10.3.6 REST OF EUROPE (ROE)

10.4 ASIA PACIFIC

10.4.1 CHINA

10.4.1.1 Increasing healthcare expenditure

10.4.2 JAPAN

10.4.2.1 Advanced healthcare infrastructure to support market growth in Japan

10.4.3 INDIA

10.4.3.1 Expanding healthcare sector in the country to drive market growth

10.4.4 REST OF ASIA PACIFIC (ROAPAC)

10.5 REST OF THE WORLD (ROW)

10.5.1 LATIN AMERICA

10.5.1.1 Increasing number of cancer screening programs to support market growth

10.5.2 MIDDLE EAST & AFRICA

10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to support market growth

11 COMPETITIVE LANDSCAPE (Page No. - 123)

11.1 OVERVIEW

11.2 MARKET SHARE ANALYSIS, 2019

11.3 COMPETITIVE SCENARIO

11.3.1 PRODUCT LAUNCHES (2017�2020)

11.3.2 PRODUCT APPROVALS (2017�2020)

11.3.3 PARTNERSHIPS AND COLLABORATIONS (2017�2020)

11.3.4 ACQUISITIONS (2017�2020)

11.4 COMPETITIVE LEADERSHIP MAPPING (2018)

11.4.1 VENDOR INCLUSION CRITERIA

11.4.2 VISIONARY LEADERS

11.4.3 DYNAMIC DIFFERENTIATORS

11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. - 129)

(Business overview, Products offered, Recent developments, MNM view)*

12.1 ROCHE

12.2 DANAHER

12.3 THERMO FISHER SCIENTIFIC

12.4 ABBOTT

12.5 AGILENT TECHNOLOGIES

12.6 MERCK KGAA

12.7 SAKURA FINETEK JAPAN

12.8 ABCAM

12.9 BECTON, DICKINSON AND COMPANY (BD)

12.10 BIO SB

12.11 BIOGENEX

12.12 CELL SIGNALING TECHNOLOGY

12.13 HISTO-LINE LABORATORIES

12.14 SLEE MEDICAL GMBH

12.15 AMOS SCIENTIFIC PTY LTD

12.16 JINHUA YIDI MEDICAL APPLIANCE CO.LTD

12.17 MEDITE GMBH

12.18 CELLPATH LTD

12.19 HOLOGIC, INC.

12.20 DIPATH S.P.A.

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 166)

13.1 INDUSTRY INSIGHTS

13.2 DISCUSSION GUIDE

13.3 KNOWLEDGE STORE: MARKETSANDMARKETS� SUBSCRIPTION PORTAL

13.4 AVAILABLE CUSTOMIZATIONS

13.5 RELATED REPORTS

13.6 AUTHOR DETAILS



LIST OF TABLES (127 TABLES)

TABLE 1 NUMBER OF PATHOLOGIST PER 100,000 POPULATION, BY COUNTRY, 2018

TABLE 2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 3 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018�2025 (USD MILLION)

TABLE 4 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2018�2025 (USD MILLION)

TABLE 5 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2018�2025 (USD MILLION)

TABLE 6 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2018�2025 (USD MILLION)

TABLE 7 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2018�2025 (USD MILLION)

TABLE 8 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2018�2025 (USD MILLION)

TABLE 9 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018�2025 (USD MILLION)

TABLE 10 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2018�2025 (USD MILLION)

TABLE 11 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2018�2025 (USD MILLION)

TABLE 12 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2018�2025 (USD MILLION)

TABLE 13 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2018�2025 (USD MILLION)

TABLE 14 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2018�2025 (USD MILLION)

TABLE 15 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 16 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2018�2025 (USD MILLION)

TABLE 17 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2018�2025 (USD MILLION)

TABLE 18 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT, BY REGION, 2018�2025 (USD MILLION)

TABLE 19 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2018�2025 (USD MILLION)

TABLE 20 GLOBAL CANCER INCIDENCE, 2018 VS.2025

TABLE 21 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018�2025 (USD MILLION)

TABLE 22 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 23 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2018�2025 (USD MILLION)

TABLE 24 STOMACH CANCER INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 25 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2018�2025 (USD MILLION)

TABLE 26 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 27 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 28 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2018�2025 (USD MILLION)

TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 30 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2018�2025 (USD MILLION)

TABLE 31 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025

TABLE 32 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2018�2025 (USD MILLION)

TABLE 33 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018�2025 (USD MILLION)

TABLE 34 TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 35 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018�2025 (USD MILLION)

TABLE 36 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2018�2025 (USD MILLION)

TABLE 37 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2018�2025 (USD MILLION)

TABLE 38 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018�2025 (USD MILLION)

TABLE 39 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018�2025 (USD MILLION)

TABLE 40 TISSUE DIAGNOSTICS MARKET, BY REGION, 2018�2025 (USD MILLION)

TABLE 41 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018�2025 (USD MILLION)

TABLE 42 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 43 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018�2025 (USD MILLION)

TABLE 44 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018�2025 (USD MILLION)

TABLE 45 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018�2025 (USD MILLION)

TABLE 46 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 47 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 48 US CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 49 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 50 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 51 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 52 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 53 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 54 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 55 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 56 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018�2025 (USD MILLION)

TABLE 57 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 58 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018�2025 (USD MILLION)

TABLE 59 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018�2025 (USD MILLION)

TABLE 60 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018�2025 (USD MILLION)

TABLE 61 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 62 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 63 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 64 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 65 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 66 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 67 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 68 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 69 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 70 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 71 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 72 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 73 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 74 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 75 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 76 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 77 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 78 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 79 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 80 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 81 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 82 KEY REST OF EUROPEAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025

TABLE 83 KEY REST OF EUROPEAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025

TABLE 84 KEY REST OF EUROPEAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025

TABLE 85 ROE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 86 ROE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 87 ROE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 88 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018�2025 (USD MILLION)

TABLE 89 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 90 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018�2025 (USD MILLION)

TABLE 91 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018�2025 (USD MILLION)

TABLE 92 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018�2025 (USD MILLION)

TABLE 93 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 94 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 95 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 96 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 97 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 98 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 99 JAPAN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 100 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 101 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 102 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 103 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 104 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 105 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 106 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 107 INCIDENCE OF CANCER IN ROPAC

TABLE 108 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 109 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 110 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 111 ROW: TISSUE DIAGNOSTICS MARKET, BY REGION, 2018�2025 (USD MILLION)

TABLE 112 ROW: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 113 ROW: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018�2025 (USD MILLION)

TABLE 114 ROW: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018�2025 (USD MILLION)

TABLE 115 ROW: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018�2025 (USD MILLION)

TABLE 116 ROW: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 117 ROW: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 118 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025

TABLE 119 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025

TABLE 120 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025

TABLE 121 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 122 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 123 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)

TABLE 124 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025

TABLE 125 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018�2025 (USD MILLION)

TABLE 126 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018�2025 (USD MILLION)

TABLE 127 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018�2025 (USD MILLION)



LIST OF FIGURES (38 FIGURES)

FIGURE 1 RESEARCH DESIGN

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

FIGURE 4 MARKET SIZE ESTIMATION FROM THE PARENT MARKET

FIGURE 5 DATA TRIANGULATION METHODOLOGY

FIGURE 6 TISSUE DIAGNOSTIC MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)

FIGURE 7 TISSUE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)

FIGURE 8 TISSUE DIAGNOSTIC MARKET, BY DISEASE, 2020 VS. 2025 (USD MILLION)

FIGURE 9 TISSUE DIAGNOSTIC MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)

FIGURE 10 GEOGRAPHIC SNAPSHOT OF THE GLOBAL TISSUE DIAGNOSTIC MARKET

FIGURE 11 RISING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF THE TISSUE DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

FIGURE 12 GASTRIC CANCER SEGMENT DOMINATED THE APAC MARKET IN 2019

FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

FIGURE 14 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS

FIGURE 15 CURRENT HEALTH EXPENDITURE PER CAPITA

FIGURE 16 CURRENT HEALTH EXPENDITURE (% OF GDP)

FIGURE 17 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012�2016

FIGURE 18 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2010�2019)

FIGURE 19 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2010�2019

FIGURE 20 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2010�2019

FIGURE 21 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2010�2019

FIGURE 22 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2010�2018

FIGURE 23 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2010�2018

FIGURE 24 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2010�2019

FIGURE 25 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT

FIGURE 26 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT

FIGURE 27 PRODUCT LAUNCHES-THE MOST ADOPTED GROWTH STRATEGY FROM 2017 TO 2020

FIGURE 28 SHARES OF TOP COMPANIES IN THE GLOBAL TISSUE DIAGNOSTIC MARKET (2019)

FIGURE 29 TISSUE DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING

FIGURE 30 ROCHE: COMPANY SNAPSHOT (2019)

FIGURE 31 DANAHER: COMPANY SNAPSHOT (2019)

FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)

FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019)

FIGURE 34 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019)

FIGURE 35 MERCK: COMPANY SNAPSHOT (2019)

FIGURE 36 ABCAM: COMPANY SNAPSHOT (2019)

FIGURE 37 BD: COMPANY SNAPSHOT (2019)

FIGURE 38 HOLOGIC, INC: COMPANY SNAPSHOT (2019)